Partnerships to Advance Cancer Health Equity (PACHE) Program
Interactive Virtual Technical Assistance Workshop
July 15, 2020

Webinar Date/Time
Wednesday, July 15, 2020
11:00 a.m.–4:30 p.m. EDT
Contact Information
For webinar-related questions please contact:
Michelle Murray


Direct questions regarding the Workshop to our logistics contractor:

Michelle L. Murray, CMP, CVEP
Conference Group Manager
NOVA Research Company

TAW Contact List for Navigation, GMaP and, General Programmatic Assistance

Hana Odeh, Ph.D.
Program Director and Training Navigator
(240) 276-5572
Training Navigation (TN)

Anil Wali, Ph.D.
GMaP Program Director
(240) 276-6183
Geographic Management of Cancer Health Disparities Program (GMaP)

Mary Ann S. Van Duyn, Ph.D., M.P.H.
Associate Deputy Director for Integration
(240) 751-5601

Peter Ogunbiyi, Ph.D., D.V.M.
Diversity Training Branch, Chief
(240) 276-6176

Alison Lin, Ph.D.
Diversity Training Branch, Deputy Chief (iCURE contact)
(240) 276-6177
Intramural Continuing Umbrella of Research Experiences (iCURE)

CURE/CRCHD Program Directors

Samson Y. Gebreab, Ph.D., M.Sc.
Program Director
(240) 276-6652
Diversity Research Supplement (PA-20-222)
Diversity Research Supplement to Promote Re-Entry (PA-18-592)

John Ojeifo, M.D., Ph.D., M.B.A.
Program Director
(240) 276-6186
Mentored Clinical Scientist Career Development Awards to Promote Diversity (K08 No Independent Clinical Trial PAR-18-337; K08 Clinical Trial Required PAR-18-336)
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (PAR-18-731)

Mulualem Tilahun, D.V.M., Ph.D.
Program Director
(240) 276-7360
Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial PAR-18-364; K01 Clinical Trial Required PAR-18-365)
Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials PAR-18-366; K22 Clinical Trial Required PAR-18-367)

Tiffany Wallace, Ph.D.
Program Director
(240) 276-5114
Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed PAR-18-654; R21 Clinical Trial Not Allowed PAR-18-655)